Sequencing upstart raises $273M ahead of IPO; Aceragen acquires highly-anticipated Farber disease treatment
University of Oxford spinout Oxford Nanopore has raised a monster round for its “scalable” DNA and RNA sequencing tech ahead of a reported IPO filing in London.
Once caught up in the Woodford debacle, the sequencing group has raised £195 million — $273 million — with the help of a roster of new investors. Temasek, Wellington Management, M&G Investments and Nikon pitched in £125 million of that while existing investors ponied up the rest.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
